Items where authors include "Coens, C"

Article

Musoro, JZ, Coens, C, Sprangers, MAG et al. (18 more authors) (2023) Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types. European Journal of Cancer, 188. pp. 171-182. ISSN 0959-8049

Pe, M, Alanya, A, Falk, RS et al. (25 more authors) (2023) Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures. The Lancet Oncology, 24 (6). e270-e283. ISSN 1470-2045

Koller, M, Musoro, JZ, Tomaszewski, K et al. (8 more authors) (2022) Corrigendum to “Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma – Interpretation guidance derived from two randomized EORTC trials” [Lung Cancer 167C (2022) 65–72]. Lung Cancer, 171. p. 126. ISSN 0169-5002

Machingura, A, Taye, M, Musoro, J et al. (19 more authors) (2022) Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: validation study. European Journal of Cancer, 170. pp. 1-9. ISSN 0959-8049

Koller, M, Musoro, JZ, Tomaszewski, K et al. (8 more authors) (2022) Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma – Interpretation guidance derived from two randomized EORTC trials. Lung Cancer. ISSN 0169-5002

Gamper, EM, Musoro, JZ, Coens, C et al. (9 more authors) (2021) Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials. BMC cancer, 21 (1). 1083. ISSN 1471-2407

Dirven, L, Musoro, JZ, Coens, C et al. (13 more authors) (2021) Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients. Neuro-Oncology, 23 (8). pp. 1327-1336. ISSN 1522-8517

Musoro, JZ, Sodergren, SC, Coens, C et al. (11 more authors) (2020) Minimally important differences for interpreting the EORTC QLQ‐C30 in advanced colorectal cancer patients treated with chemotherapy. Colorectal Disease, 22 (12). pp. 2278-2287. ISSN 1462-8910

Musoro, JZ, Coens, C, Greimel, E et al. (10 more authors) (2020) Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer. Gynecologic Oncology, 159 (2). pp. 515-521. ISSN 0090-8258

Musoro, JZ, Coens, C, Singer, S et al. (12 more authors) (2020) Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer. Head & Neck, 42 (11). pp. 3141-3152. ISSN 1043-3074

Ray-Coquard, I, Hatcher, H, Bompas, E et al. (16 more authors) (2020) A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113). International Journal of Gynecological Cancer. ISSN 1048-891X

Coens, C, Pe, M, Dueck, AC et al. (32 more authors) (2020) International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. The Lancet Oncology, 21 (2). e83-e96. ISSN 1470-2045

Mierzynska, J, Taye, M, Pe, M et al. (14 more authors) (2020) Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. European Journal of Cancer, 125. pp. 69-82. ISSN 0959-8049

Mierzynska, J, Piccinin, C, Pe, M et al. (10 more authors) (2019) Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review. The Lancet Oncology, 20 (12). e685-e698. ISSN 1470-2045

Bottomley, A, Reijneveld, JC, Koller, M et al. (30 more authors) (2019) Current state of quality of life and patient-reported outcomes research. European Journal of Cancer, 121. pp. 55-63. ISSN 0959-8049

Musoro, JZ, Coens, C, Frederic, F et al. (9 more authors) (2019) Minimally important differences for interpreting EORTC QLQ-C30 scores in patients with advanced breast cancer. JNCI: Journal of the National Cancer Institute, 3 (3). pkz037. ISSN 0027-8874

Bottomley, A, Pe, M, Sloan, J et al. (38 more authors) (2018) Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials. Clinical Trials, 15 (6). pp. 624-630. ISSN 1740-7745

Musoro, JZ, Bottomley, A, Coens, C et al. (8 more authors) (2018) Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma. European Journal of Cancer, 104. pp. 169-181. ISSN 0959-8049

Pe, M, Dorme, L, Coens, C et al. (29 more authors) (2018) Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. The Lancet Oncology, 19 (9). E459-E469. ISSN 1470-2045

Kluetz, PG, Kanapuru, B, Lemery, S et al. (25 more authors) (2018) Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop. Value in Health, 21 (6). pp. 742-747. ISSN 1098-3015

Musoro, ZJ, Hamel, J-F, Ediebah, DE et al. (10 more authors) (2018) Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocol. BMJ Open, 8 (1). e019117.

Bottomley, A, Pe, M, Sloan, J et al. (36 more authors) (2016) Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncology, 17 (11). e510-e514. ISSN 1470-2045

Ghislain, I, Zikos, E, Coens, C et al. (11 more authors) (2016) Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials. The Lancet Oncology, 17 (7). e294-e304. ISSN 1470-2045

Zikos, E, Coens, C, Quinten, C et al. (16 more authors) (2016) The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative. Journal of the National Cancer Institute, 108 (5). ISSN 0027-8874

Quinten, C, Coens, C, Ghislain, I et al. (17 more authors) (2015) The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients. European journal of cancer, 51 (18). 2808 - 2819. ISSN 0959-8049

Bogaerts, J, Sydes, MR, Keat, N et al. (43 more authors) (2014) Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. European journal of cancer. ISSN 0014-2964

Conference or Workshop Item

Machingura, A, Musoro, J, Ringash, J et al. (29 more authors) (2020) 3167 Clustering of EORTC QLQ-C30 health-related quality of life scales across several disease sites. In: 27th Annual Conference of the International Society for Quality of Life Research, 19-23 Oct 2020, Online.

Bjelic-Radisic, V, Cardoso, F, Velikova, G orcid.org/0000-0003-1899-5942 et al. (7 more authors) (2020) Abstract OT3-16-01: Follow-up in early (EBC) and locally advanced (LABC) breast cancer patients; EORTC protocol 1617-QLG-BCG-ROG. In: 2019 San Antonio Breast Cancer Symposium, 10-14 Dec 2019, San Antonio, Texas.

Proceedings Paper

Machingura, A, Musoro, J, Taye, M et al. (19 more authors) (2022) Does baseline health-related quality of life scores (QLQC30) add prognostic value beyond clinical measures and improve prognostic accuracy in cancer RCTs? In: Quality of Life Research. 29th Annual Conference of the International Society for Quality of Life Research, 19-22 Oct 2022, Prague, Czech Republic. Springer , S83-S83.

Musoro, JZ, Coens, C, Sprangers, MAG et al. (14 more authors) (2022) Synthesis of anchor-based minimally important differences (MID) for the EORTC QLQ-C30 scales across nine cancer sites. In: Quality of Life Research. 29th Annual Conference of the International Society for Quality of Life Research, 19-22 Oct 2022, Prague, Czech Republic. Springer , S47-S48.

Rousta, P, Coens, C, Pe, M et al. (20 more authors) (2022) Minimally Important Differences (MID) by Anchoring to Patients' Rating of Change in Oncology: A Systematic Review. In: Quality of Life Research. 29th Annual Conference of the International Society for Quality of Life Research, 19-22 Oct 2022, Prague, Czechia. Springer , S48.

Machingura, A, Taye, M, Musoro, J et al. (18 more authors) (2021) Does change in health-related quality of life scores (QLQ-C30) add prognostic value beyond clinical measures and improve prognostic accuracy in cancer RCTs? In: Quality of Life Research. 28th Annual Conference of the International Society for Quality of Life Research, 12-28 Oct 2021, Online. Springer Nature , S92-S92.

Piccinin, C, Kulis, D, Bottomley, A et al. (6 more authors) (2019) Development of scientific guidelines for use of the eortc item library in cancer clinical trials. In: Value in Health. ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, 18-22 May 2019, New Orleans, LA, USA. Elsevier Ltd. , S112-S113.